

Estimation of the In-Vitro Synergistic Effect of Vancomycin with Bacteriophage and its Endolysin on Iraqi Local Isolates of *Enterococcus faecalis*

Rand R. Hafidh¹, Zainab Oday Hamed², Abdullah A. Awni³, Manal N. Jassas⁴

¹Department of Microbiology, College of Medicine, University of Baghdad, Baghdad, Iraq.

²Department of pharmacy, Baghdad College of Medical Sciences, Baghdad, Iraq.

³Ministry of Health, Baghdad Health Directorate -Al-Karkh, Al-Furat General Hospital, Baghdad, Iraq.

⁴Microbiology Division, Laboratory Department, Ghazi Hariri Hospital for Specialized Surgery, Baghdad, Iraq.

*Corresponding Author.

Received 14/11/2022, Revised 30/05/2023, Accepted 01/06/2023, Published Online First 20/11/2023,
Published 1/6/2024



© 2022 The Author(s). Published by College of Science for Women, University of Baghdad.

This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Enterococcus faecalis is known to cause many serious infections with an upsurge in the development of antibiotic resistant strains, especially vancomycin. Lytic bacteriophage and its endolysin have the potential to affect and lyse specific bacterial cells making them a possible alternative therapy to antibiotic resistant strains. The study aimed to investigate the synergistic effect of phage/ phage cocktail/ endolysin with vancomycin on *E. faecalis* isolated from urine samples. The antibiotic resistant profile 17 *E. faecalis* was done with an emphasis on the sensitivity to vancomycin. The lytic phages were isolated from the local environment. The infectivity and the coverage rate for the phage and phage cocktail were calculated. The enzyme of the lytic phage was isolated by chromatography. The synergistic effect was tested by turbidity reduction assay to evaluate the growth reduction level. It had been found that 6/17 *E. faecalis* isolates were resistant to vancomycin, 7/17 isolates were intermediate, and 4/17 were susceptible. Three lytic phages were identified with an infectivity rate of 100%, 76.4%, and 88.2%. The phage cocktail yielded 100% rate of infectivity and 91.6 % coverage rate. The reduction in the growth levels of the 17 *E. faecalis* after treatment with phage / phage cocktail/ vancomycin/ mixture of vancomycin and phage cocktail was effective. The synergistic effect of vancomycin together with the phage cocktail significantly reduced the growth of 70.6% of the isolates. The antibacterial activity of vancomycin plus endolysin treatment was revealed in a time dependent manner. Thus, the synergistic effect of vancomycin with phage/ endolysin illustrated an effective method to treat the antibiotic-resistant strains of *E. faecalis* to overcome this emerging clinical problem.

Keywords: Bacteriophages, *Enterococcus faecalis*, Endolysin, Multidrug resistance bacteria, Phage therapy, Phage cocktail.

Introduction

The Gram-positive non-spore-forming bacterium; *Enterococcus faecalis*, is an inhabitant of the

gastrointestinal tract. It is known to be an essential commensal member of the human gut. The

emergence of Multi-Drug Resistant (MDR) variants is due to a remarkable ability of the bacterium to adapt to different environments and a tendency to acquire antibiotic resistance gene¹. In susceptible hosts, *E. faecalis* can act as an opportunistic pathogen producing severe and life-threatening infections, including bacteremia, endocarditis, urinary tract infections (UTI), catheter-related infections, intra-abdominal and pelvic infections, and wound infections².

Antimicrobial resistance poses an increasingly important public health challenge as it causes thousands of deaths every year that can be increased to millions of deaths worldwide³. Scientists worldwide are inspired to search for viable alternatives due to the high incidence of MDR bacteria and the inadequacy of existing antibiotics to overwhelm infectious diseases, particularly, urinary tract infections⁴⁻⁶.

Bacteriophages or phages, also known as viral predators of bacteria, are viruses that infect and replicate only in bacterial cells. They are widely distributed in the environment. They are different in size, morphology, and genomic content⁷. Similar to all viruses, bacteriophages are very species-specific to their hosts. They have specific interactions with the bacterial host. They infect a single bacterial

species or even specific strains within a species⁸. Phages can be mixed with other phages having different host ranges. This phage-phage mixture can be described as a phage cocktail and it is proven to be active against many MDR bacteria⁹.

Bacteriophages or phages, with their related cell-wall lysing enzymes (endolysins), have the ability to be useful tools to tackle MDR bacteria¹⁰. Many studies indicate the potential of phages and their endolysins as suitable alternatives to treat *E. faecalis*^{11, 12}. A recent study has come to the fact that a combination of a phage and an antibiotic has better killing efficiency against *E. faecalis*¹³. In addition, *E. faecalis* vancomycin-resistant strains have been used for screening to understand the potential of phages as novel therapeutic agents¹⁴.

Dependently, the current study tried to investigate the synergistic effect of vancomycin with phage cocktail then vancomycin with endolysin on the reduction level of *Enterococcus faecalis* growth, isolated from urine samples. The investigated synergistic effect was also compared with the growth reduction level after treatment with phage alone, phage cocktail, and phage endolysin. Thus, unveil a new era of MDR bacteria treatment and their associated critical diseases by objects from Mother Nature.

Materials and Methods

Bacterial Samples

An experimental study was conducted to isolate 79 *E. faecalis* from urine specimens. The samples were collected from patients with UTI attending Al-Furat General Hospital and Ghazi Hariri Hospital for Specialized Surgery, Baghdad, Iraq in the period from Oct. to Dec. 2021. All the samples have undergone a series of identification and confirmatory tests to isolate and identify *E. faecalis*.

Isolation and Primary Identification of *Enterococcus* spp.

Azide Blood Agar Base medium

The collected urine samples were cultured on a selective blood agar medium; Azide Blood Agar Base and incubated at 37 °C overnight. This medium is recommended for the isolation and

cultivation of clinical and nonclinical samples of *Enterococci*, *Streptococci*, and *Staphylococci*. The growth of gram-negative bacteria was inhibited by sodium azide while sparing the growth of *Enterococci*, *Streptococci*, and *Staphylococci*¹⁵.

Bile Esculin Agar Medium

After overnight incubation, the bacterial growth from Azide Blood Agar Base medium was transferred to Bile Esculin Agar plates. This test is used to identify and differentiate *Enterococci* and group D *Streptococci* from non-group D Viridans group *Streptococci*, which grow poorly on bile. The identified bacteria are bile tolerant and can hydrolyze esculin to esculetin¹⁵. The cultured plates were incubated at 37 °C for overnight.

Confirmatory Identification and Antibiotic resistant Profile

The identification of a species-level and the antibiotic sensitivity profile was confirmed by VITEK 2 Compact System. The instructions of the manufacturer were followed to prepare the bacterial samples. Blood agar with overnight bacterial cultures was used. The VITEK 2 Compact system uses a Gram-positive cocci identification kit (ID-GP) as a fluorogenic recognition method in less than eight hrs. While a turbidimetric susceptibility test in less than 18 hrs was used for bacterial sensitivity of all the isolates against sixteen antibiotics. The percentage of the resistant rate was measured as follows¹⁶:

No. of resistant isolates/ total No. of tested isolates*100

Sensitivity Test against vancomycin

Agar-Disc Diffusion Assay

The antimicrobial susceptibility for all the isolates was tested as described by¹³. The bacterial suspension was prepared by transferring of few colonies; two to four, from overnight Brain Heart Infusion agar to 2 ml normal saline. The bacterial suspension was adjusted to (0.5 McFarland) turbidity which is equal to 1.5×10^8 CFU/ml. The bacterial suspension was inoculated onto a Mueller Hinton agar plate by a sterile cotton swab and left to dry. Later, vancomycin antibiotic discs 30 μ g were laid on the surface of the agar medium. The inoculated plates were incubated at 37°C overnight. The assay was achieved using Kirby-Bauer disk diffusion technique¹⁷. The inhibition zone diameter of the antibiotic disc was measured and the measures were interpreted referring to the Clinical and Laboratory Standards Institute criteria¹⁸.

Minimum Inhibitory Concentration (MIC)

The broth serial dilution method was used to determine Vancomycin MIC on *E. faecalis*. The inhibition of the microorganism's visible growth after overnight incubation by the lowest concentration of vancomycin is known to be MIC¹⁹.

The interpretation of the isolates as being Resistant (R), Intermediate (I), and Susceptible (S) was

calculated according to the value breakpoints of MIC and the zone diameter $R \geq 32 \mu\text{g/ml}$ and $\leq 14\text{mm}$, $I \geq 8-16 \mu\text{g/ml}$ and $15-19\text{mm}$, and $S \leq 4 \mu\text{g/ml}$ and $\geq 20\text{mm}$ ¹⁸.

Isolation and Identification of the Bacteriophage

Characteristics of the Isolated Phage

Three phage crude suspensions were collected from sewage in the city of Baghdad during one week in Nov. 2020. About 3 ml of the crude sample was mixed with an overnight *E. faecalis* broth 100 μ l. The mixture was incubated at 37°C overnight until obtaining the specific lytic phage. The specific characteristics of the phages' plaques such as size, clarity, morphology, and margin were determined²⁰. Their titer was verified by the top layer assay²¹. The clearest and largest plaque had been selected^{21, 22}.

Spot Lyses Assay

The phage spotting technique was used to test the specific phage on nutrient agar plates. The presence of the lytic phages was concluded by the formation of inhibition zones²³. A sterile swab was used to spread an overnight cultured bacterium on nutrient agar plates to form a bacterial lawn. A phage suspension of 10 μ l was applied as spots after 10-15 min and the plates were incubated overnight at 37°C. The identified specific lytic phage was collected by a sterile pasture pipette after an overnight incubation. One ml of SM buffer (50 ml of SM buffer, the following materials were used: Sodium chloride 0.29gm, Magnesium sulfate 0.1gm, Gelatin 250 μ l (2% w/v), and 2.5 ml of Tris-HCl (1 M, pH 7.5), all the materials were mixed on a magnetic stirrer and stored at 4 C°) was used with the collected phage then gentle vortex and shaking were done for 20 sec. The mixture was centrifuged at 1000 g for three min after bacterial lyses by Chloroform (1: 10 v/ v). The required phages supposed to be in the collected supernatants were transported to a new sterile Eppendorf tube and kept at 4C°. The saved phages were kept for further tests in this study.

Bacteriophage infectivity rate

The Infectivity and the Coverage Rates of the Isolated Phages and the Developed phage Cocktail against *E. faecalis*

The infectivity rate of the three isolated phages was determined against 17 new samples of *E. faecalis* randomly collected from patients in the Medical City Hospital. In addition, the phage cocktail was formed by the addition of 100 µl of 10⁹ plaque forming unit (PFU)/ml of (BP-EF1, BP-EF2, and BP-EF3) phage stocks in 15ml tube. By applying the spot lyses assay, 10 µl of the phage/ phage cocktail suspension was spotted on the bacterial lawn. After dryness, all plates were incubated at 37°C for overnight. The next day, the susceptibility to the phage/ phage cocktail was determined by the formation of the lyses zones. Moreover, the coverage rate of the phage cocktail was determined against another 12 new samples of *E. faecalis* using the same method mentioned above ¹¹.

The infectivity and the coverage rates were calculated according to the following formula ¹¹:

The infectivity = number of bacteria lysed by phage or phage cocktail/ total number of bacteria * 100%

The coverage rate = number of bacteria lysed by phage cocktail/ total number of bacteria * 100%

Isolation of Phage Lysin

Enterococcus faecalis (EF-4) in 100 ml of Nutrient broth medium was cultured and incubated overnight at 37°C. Afterward, the bacterial growth with 250 ml of sterile Nutrient broth medium was incubated for another three hours. Ten milliliters of BP-EF2 at titer 1×10⁹ PFU/ml were mixed with EF-4 then put directly on ice for 20 min. The sediment was collected after centrifugation of the mixture at 10,000 g for 20 min. Ten milliliters of 0.05 M phosphate buffer saline plus 5mg deoxy ribonuclease was used to suspend the sediment and incubated for 60 min at 37°C. EDTA at 0.005 M was added and centrifuged at 10,000 g for 60 min then the supernatant was collected. Ammonium sulfate was supplemented to 85 % saturation then the suspension was incubated overnight at 4°C. On the next day, centrifugation at 10,000 g for 60 min was carried out to the suspension and re-suspended

in five milliliters of 0.05 M phosphate- buffered saline at (pH 7.5). Subsequently, dialysis versus 200 ml of 0.05 M phosphate buffer saline was done. Every two hours, the buffer was changed two times and left overnight at 4°C. Sephadex G100 column chromatography (3×20 cm) was used to isolate the enzyme. The dialyzed solution was added with 20 ml of 0.05 M phosphate- buffered saline at pH 7.5 as eluent. Every five minutes the elute 1 ml was collected in 50 Eppendorf tubes ^{11, 12}. A spectrophotometer was used to measure the absorbance of each fraction at 280 nm. The tube with the endolysin lytic activity was recognized in each Eppendorf tube by dropping 10 µl of the elute onto *E. faecalis* lawns ¹².

Bacteriophage and Phage Cocktail treatment with/without Vancomycin

Quantitative Analysis of the Bacterial Growth Reduction

The antibacterial activity against *E. faecalis* was measured by turbidity reduction assay: the overnight bacterial cells were centrifuged at 4000 g for 30 min and re-suspended with phosphate-buffered saline (pH 7.5). At room temperature, 30 µl of phage/ phage cocktail/ vancomycin/ mixture of vancomycin and phage cocktail were added to 270 µl of the bacterial culture broth. Then at 600 nm, the optical density was measured by spectrophotometer ¹². In order to measure and assess the antibacterial activity of phage cocktail/ lysin/ vancomycin/ vancomycin plus lysin the same procedure was followed except that the optical density was measured every 5 min for 35 min against only one bacterium EF-5.

The Bacterial concentration (CFU/ml) was measured according to the below formulae ¹¹.

$\Delta OD = OD \text{ (before treatment)} - OD \text{ (after treatment)}$

$\Delta \text{ Bacterial concentration (CFU/ml)} = \text{CFU/ml (before treatment)} - \text{CFU/ml (after treatment)}$

Data Analysis:

Microsoft Excel Version (14.0.6023.1000) was used to represent the plots and measure the percentages. Vitek 2 system with software version (5.01) was

used to evaluate the bio-resistant profile of *E. faecalis*.

Results and Discussion

Bacterial isolation and Identification

The preliminary identification of *Enterococcus* species depends mainly on the appearance of these bacteria on the selective and differentiation media in addition to the microscopic characteristics. The tests demonstrated that 27 isolates from the total 79 urine samples' isolates were identified as *Enterococcus spp.* On Azide Blood Agar Base medium *Enterococcus* species appeared as a small

glassing gray colony with no hemolysis (Fig. 1). While on Bile Esculin Agar Medium *Enterococcus* species colonies were surrounded by black halos. The dark brown or black color is due to the formation of a complex of esculetin and Fe^{3+} ions in the medium when *Enterococcus spp.* produce esculinase that hydrolyses esculin into esculetin (Fig. 2).




Figure 1. Azide Blood Agar Base medium *Enterococcus* species appears as small glassing gray colony with no hemolysis. Plates were incubated aerobically at 37°C for overnight.




Figure 2. Bile Esculin Agar Medium (A) Medium without culture. (B) Esculin hydrolysis by *Enterococcus* species. Plates were incubated aerobically at 37°C for overnight.

Confirmation and Antibioresistant Profile

Enterococcus faecalis was confirmed by VITEK 2 System with 98.99% matching value. From the 27 *Enterococcus* spp., 17 isolates were confirmed as *E. faecalis* and 10 isolates of *E. faecium* (not included in this study).

The turbidimetric susceptibility test by VITEK 2 System for 17 *E. faecalis* isolates, demonstrated variable percentages of bacterial sensitivity against the sixteen antibiotics (Table 1). The test displayed that only (29%) of the isolates were resistant to vancomycin.

Table 1. The Antibiotic susceptibility of *E. faecalis* isolates.

Antibiotic	Percentage of Resistance	Antibiotic	Resistance
Erythromycin	22 %	Oxacillin	78 %
Ciprofloxacin	8%	Inducible- clindamycin	0%
Benzylpenicillin	3%	Vancomycin	35%
Ampicillin	16 %	Gentamycin	44%
Tigecyclin	0%	Fusidic acid	11%
Levofloxacin	33%	Tobramycin	58%
Trimethoprim/sulphamethaxazole	2%	Teicoplanin	9%
Tetracyclin	32%		

Sensitivity Test against Vancomycin

Zone diameter and MIC breakpoints for the 17 *E. faecalis* isolates was shown in (Table 2). The acquired results found that 6/17 *E. faecalis* isolates

were resistant (R), 7/17 isolates were intermediate (I), and 4/17 (S) were susceptible. The rate of *E. faecalis* resistant to vancomycin was confirmed by the results given by VITEK 2 System.

Table 2. The bioresistant profile of 17 *E. faecalis* isolates against Vancomycin.

Isolate no.	Inhibition zone diameter (mm)	MIC µg /ml	Bioresistant Profile
<i>E. faecalis</i> 1	15	16	I
<i>E. faecalis</i> 2	23	4	S
<i>E. faecalis</i> 3	10	128	R
<i>E. faecalis</i> 4	33	4	R
<i>E. faecalis</i> 5	8	32	R
<i>E. faecalis</i> 6	16	8	I
<i>E. faecalis</i> 7	15	8	I
<i>E. faecalis</i> 8	15	16	I
<i>E. faecalis</i> 9	16	16	I
<i>E. faecalis</i> 10	12	128	R
<i>E. faecalis</i> 11	14	32	R
<i>E. faecalis</i> 12	8	32	R
<i>E. faecalis</i> 13	20	4	S
<i>E. faecalis</i> 14	21	4	S
<i>E. faecalis</i> 15	16	8	I
<i>E. faecalis</i> 16	16	8	I
<i>E. faecalis</i> 17	28	4	S

*R: resistant, I: intermediate, and S: susceptible.

Characteristics of the Isolated Phage

Three distinct lytic *E. faecalis* bacteriophages (BP-EF1, BP-EF2 and BP-EF3) were isolated and characterized by the top layer assay. The plaques were characterized as clear or turbid with a regular or irregular margin cut, sized from 1mm to 5mm, and had a circular shape. BP-EF2 demonstrated the largest plaque in size while BP-EF3 was the smallest one. All bacteriophages showed no hallow appearance. The results showed that all phages have sharp-regular plaque edges. In addition, BP-EF2 and BP-EF3 were turbid while BP-EF1 was clear (Table 3). The titer of the isolated bacteriophages was calculated ranging between 10^6 to 10^{12} PFU/ml.

Bacteriophage infectivity and coverage rates

The isolated bacteriophages were significantly lytic and formed an obvious clear zone on targeted bacteria. The three bacteriophages were obtained with different coverage rates of infectivity. The infectivity rates were found to be 100%, 76.4%, and 88.2% for BP-EF1, BP-EF2 and BP-EF3, respectively. An extensive overlapping was observed from mixing the three bacteriophages together yielding 100% rate of infectivity (Table 4).

Clear inhibition zones were formed by the phage cocktail on the most examined bacterial lawns. The coverage rate of the phage cocktail was shown to be 91.6 % in which 11 out of 12 *E. faecalis* bacteria were lysed (Fig. 3).

Table 3. Characterization of the isolated specific bacteriophages.

Phage	Size (mm)	Turbidity	Hallow	Plaque edge	Shape
BP-EF1	3.5	Clear	None	Sharp-regular	Circular
BP-EF2	5.0	Turbid	None	Sharp-regular	Circular
BP-EF3	1.0	Turbid	None	Sharp-regular	Circular

Table 4. Bacteriophage infectivity rate against 17 new *E. faecalis* isolates.

Bacteriophage	<i>E. faecalis</i> Isolates (n=17)	Infectivity rate (%)
BP-EF1	17/17	100
BP-EF2	13/17	76.4
BP-EF3	15/17	88.2
Phages cocktail	17/17	100





Figure 3. Clear inhibition zones on *E. faecalis* lawns by phage cocktail.

The Quantitative Growth Reduction Analysis

The growth of 11 *E. faecalis* was reduced by different levels when treated with every single phage/ phage cocktail (Table 5). BP-EF1 was able

to reduce the growth to a non-detected level of EF-4 and EF-6. BP-EF3 reduced the growth of EF-4 to a non-detected level. Significant activities against EF-1, 4, 6, and 7 were clarified by phage cocktail treatment.

The reduction in the growth levels of the 17 *E. faecalis* after treatment with phage BP-EF2/ phage cocktail/ vancomycin/ mixture of vancomycin and phage cocktail was tested. The effectiveness of the treatment was clear when the bacteria were treated with phage cocktail, vancomycin, and a mixture of vancomycin plus phage cocktail in comparison to treatment with BP-EF2 alone or vancomycin (Table 6). The synergistic effect of vancomycin together with the phage

cocktail significantly reduced the growth of EF-1, 4, 6, 7, 9, 10, 11, 13, 14, 15, 16, and 17.

Moreover, the synergistic effect of vancomycin with the extracted endolysin was tested (Table 7 and Fig. 4). By bringing the antibacterial activity of both vancomycin and the endolysin together, a significant reduction in EF-4 growth was revealed especially after 20 min and more.

Table 5. the growth reduction analysis was investigated after treatment with phage versus phage cocktail.

#	Initial (CFU/mL)	BP-EF 1	BP-EF2	BP-EF3	Phage cocktail
EF-1	1.3 * 10 ¹⁰	2.6*10 ⁵	2.5*10 ⁷	1.4*10 ⁷	-
EF-2	4.5* 10 ⁹	1.7.*10 ⁶	1.7*10 ⁷	1.3*10 ⁶	0.2*10 ⁷
EF-3	9.2 * 10 ⁹	3.5*10 ⁶	4.4*10 ⁷	0.7*10 ⁷	0.1*10 ⁶
EF-4	3.2 * 10 ⁹	-	1.2*10 ⁶	-	-
EF-5	4.3* 10 ¹¹	0.7*10 ⁷	1.4*10 ⁵	1.2*10 ⁷	0.5*10 ²
EF-6	5.7 * 10 ⁸	-	0.2*10 ⁷	1.2*10 ⁷	-
EF-7	5.6 * 10 ⁷	1.2*10 ⁵	3.5.*10 ⁶	2.7*10 ⁶	-
EF-8	1.9 * 10 ¹⁰	0.5*10 ⁷	1.1*10 ⁷	2.4*10 ⁶	0.3*10 ⁵
EF-9	3.3 * 10 ⁹	0.5*10 ⁵	1.2.3*10 ⁷	2.4.*10 ⁸	-
EF-10	2.8 * 10 ⁹	1.4*10 ⁶	1.4*10 ⁷	1.2*10 ⁷	-
EF-11	5.1 * 10 ⁹	0.2*10 ⁵	0.3.1*10 ⁶	1.7*10 ⁶	-

Table 6. The growth reduction analysis was investigated after treatment with phage BP-EF2, phage cocktail, vancomycin, and vancomycin plus phage cocktail.

<i>E. faecalis</i>	Initial (CFU/mL)	Vancomycin (CFU/mL)	Phage (BP-EF2)	Phage cocktail (CFU/mL)	Phage cocktail + vancomycin (CFU/mL)
EF-1	2.3 * 10 ¹¹	5.6 * 10 ⁷	1.2 * 10 ³	5.7 * 10 ²	-
EF-2	1.6 * 10 ¹⁰	6.6 * 10 ⁹	7.1 * 10 ⁴	8.8 * 10 ¹	2.3 * 10 ¹
EF-3	3.9 * 10 ⁴	8.2 * 10 ²	9.1 * 10 ¹	8.8 * 10 ¹	4.8 * 10 ¹
EF-4	1.6 * 10 ⁸	5.5 * 10 ⁵	8.4 * 10 ³	-	-
EF-5	2.6 * 10 ¹²	8.4 * 10 ¹⁰	1.9 * 10 ⁵	5.4 * 10 ²	2.6 * 10 ²
EF-6	2.2 * 10 ⁸	7.7 * 10 ⁶	7.1 * 10 ⁴	6.5 * 10 ²	-
EF-7	3.2 * 10 ⁷	9.1 * 10 ⁶	5.4 * 10 ⁴	6.9 * 10 ²	-
EF-8	3.1 * 10 ¹¹	4.7 * 10 ⁸	3.9 * 10 ⁶	1.9 * 10 ⁴	5.2 * 10 ²
EF-9	4.8 * 10 ⁷	4.8 * 10 ⁴	4.8 * 10 ²	5.5 * 10 ²	-
EF-10	7.8 * 10 ¹⁰	7.7 * 10 ⁸	1.3 * 10 ⁵	5.1 * 10 ²	-
EF-11	5.7 * 10 ⁷	3.9 * 10 ⁵	8.6 * 10 ²	-	-
EF-12	1.6 * 10 ¹⁰	2.8 * 10 ⁹	9.5 * 10 ⁶	6.6 * 10 ³	3.1 * 10 ³
EF-13	8.9 * 10 ⁶	8.9 * 1 ⁴	8.9 * 10 ³	8.9 * 10 ¹	-
EF-14	5.1 * 10 ⁸	5.8 * 10 ⁵	9.7 * 10 ³	7.3 * 10 ²	-
EF-15	9.4 * 10 ¹¹	2.8 * 10 ⁷	6.9 * 10 ³	-	-
EF-16	9.8 * 10 ¹¹	6.6 * 10 ⁹	9.1 * 10 ⁵	2.3 * 10 ²	-
EF-17	4.6 * 10 ¹¹	5.5 * 10 ⁷	1.1 * 10 ⁴	9.7 * 10 ³	-

Table 7. The growth reduction analysis was investigated after treating EF-4 with phage cocktail, lysin, vancomycin and vancomycin plus lysin by different time intervals.

Time	Vancomycin (CFU/mL)	phage coocail treatment (CFU/mL)	Lysin (CFU/mL)	lysin + vancomycin (CFU/mL)
0	$2.6 * 10^{12}$	$2.6 * 10^{12}$	$2.6 * 10^{12}$	$2.6 * 10^{12}$
5	$9.4 * 10^{11}$	$4.4 * 10^8$	$9.1 * 10^{10}$	$3.1 * 10^4$
10	$9.4 * 10^{11}$	$7.7 * 10^8$	$9.9 * 10^4$	$2.2 * 10^3$
15	$8.7 * 10^{10}$	$4.1 * 10^7$	$1.8 * 10^3$	$2.9 * 10^3$
20	$6.3 * 10^8$	$1.9 * 10^5$	$5.4 * 10^2$	0
25	$3.2 * 10^7$	$4.8 * 10^3$	0	0
30	0	0	0	0
35	0	0	0	0




Figure 4. The flow chart shows the significant reduction by log value in EF-5 growth after treatment with phage cocktail, lysin, vancomycin and vancomycin plus lysin starting from time zero to 35 min.

Discussion

One of the common causes of UTI is *E. faecalis* with an increasing rate of cases. It has an intrinsic resistance to a lot of antimicrobials and has the ability to develop resistance to a wide range of antibiotics causing many serious infections like UTI ^{24, 25}.

In the present study, *E. faecalis* from urine samples was found to be resistant in about 78%, 58%, 44%, and 33% to Oxacillin, Tobramycin, Gentamycin, and Levofloxacin, respectively. Unlikely, the susceptibility was found to be with Tigecyclin and Inducible- clindamycin. The susceptibility to Tigecyclin among the isolates from urine samples was similar to a previous study done in our

laboratory ¹¹. The antibiotic resistance genes in *E. faecalis* isolated from urine samples are alarming the researchers, since these genes have the ability to transmit among enterococci ²⁵. The current study found that only 35% of the isolates were resistant to vancomycin which came with some similarity with a study done by Ghalavand, Z. in 2020, who found that *E. faecalis* isolated from urine sample was sensitive to vancomycin ²⁶. The goal of the current study was to compare the antibacterial influence of vancomycin and the phage alone or together. Therefore, the susceptibility to vancomycin is required to test its antibacterial effect and compare it with the subjects.

It is quite clear that the intrinsic and the acquired antibiotic resistance in *E. faecalis* have prone to extensive drug resistance²⁷. In addition, mutations of the bacterial cell wall-associated polysaccharide or membrane protein increase the chance of resistance to phage therapy²⁸. Therefore, the synergistic effect of phage and antibiotic as a combined treatment shows great promise as an effective therapy in comparison to treatment with phage or antibiotic alone²⁹. The strategy behind the combined treatment is due to the variations in the mechanisms of action between phage and antibiotics³⁰⁻³².

The isolation of the specific *E. faecalis* lytic phage was previously done in our laboratory. The effectiveness of the phage cocktail and phage endolysin to diminish bacterial growth was also proved¹¹. The effectiveness of endolysin to eliminate *E. faecalis* biofilm was significantly quantified¹². Hence, further analysis was required to test the effect of the combined treatment with an antibiotic on this uropathogen.

The results estimated that treating *E. faecalis* with a phage cocktail had shown an advantage over a single phage therapy. The infectivity rates were found to be 100%, 76.4%, and 88.2% for BP-EF1, BP-EF2 and BP-EF3, respectively. Though, mixing the three bacteriophages together yields 100% rate of infectivity and can lyse 91.6 % of the tested *E. faecalis*.

The quantitative analysis for the growth reduction level was also significantly reduced when using a phage cocktail than phage BP-EF2 alone or vancomycin alone. In which, four *E. faecalis* were completely defeated by the cocktail therapy.

In contrast, a mixture of vancomycin and phage cocktail had the power to reduce the growth level to zero in 11 *E. faecalis*. These may be attributed to the

Conclusion

E. faecalis is known to cause many serious infections and is increasingly producing strains resistant to antibiotics, especially vancomycin. Lytic phages and their endolysins have the potential

mechanism of action of vancomycin together with the phage cocktail in reducing the growth rate.

Many studies suggest the use of phages as an adjuvant with the antibiotic as an effective therapeutic strategy for treating infectious diseases caused by multidrug-resistant bacteria^{33, 34}. Moreover, a synergistic effect was demonstrated when combining bacteriophage lysine with different antibiotics. Bacteriophage lysins or endolysins are hydrolytic enzymes produced by bacteriophages during the final stage of the lytic cycle to allow cleavage through the host's cell and release of the phage's new progeny after multiplication inside the bacteria³⁵.

In the current study a considerable reduction in EF-4 growth by 3 logs and 5 logs when treated with vancomycin and a single phage, respectively, was detected. However, treatment with phage cocktail or phage cocktail plus vancomycin reduces the growth to a non-detectable level. The same bacteria were treated by different time intervals and the growth was minimized to an undetected level after 30 min treatment with vancomycin or phage cocktail alone. In comparison, 25 min was required to kill the bacteria after lysine treatment and 20 min was enough when lysine was combined with vancomycin.

The restrictions in this study were the need to increase the isolates number to be tested. Further, *in vivo* investigations are required to verify the validity of the antibiotic-phage combination.

It is very clear that the urge to develop a new therapeutic approach to overcome the rapid development of antibiotic resistant strains among *E. faecalis* has become crucial. Thus, many studies are still in need to battle the rapid bacterial transformation.

to affect and lyse certain bacterial cells, making them a potential alternative therapy for antibiotic-resistant strains. An antibiotic resistance profile of 17 *E. faecalis* isolated from urine samples was

established, focusing on susceptibility to vancomycin. Lytic phages were isolated from the local environment. Three lytic phages were identified with infection rates of 100%, 76.4%, and 88.2%, respectively. The synergistic effect of vancomycin with the phage cocktail significantly reduced the growth of 70.6% of the isolates. The combined effects of phage/endolysin and

vancomycin have a significant reduction effect on the bacterial growth in a time dependent manner. Interestingly, the combination treatment produced a significant synergy in reducing the growth of *E. faecalis* compared with either treatment alone. Therefore, the synergistic effect could facilitate the future development of the treatment of antibiotic-resistant *E. faecalis*.

Acknowledgment

The cooperation of the laboratory staff in Al-Furat General Hospital and Ghazi Hariri Hospital for Specialized Surgery is appreciated.

Authors' Declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images, that are not ours, have been included with the necessary permission for

re-publication, which is attached to the manuscript.

- Authors sign on ethical consideration's approval.
- Ethical Clearance: The project was approved by the local ethical committee at University of Baghdad, No. 134 in the 12th of May 2021.

Authors' Contribution Statement

All the authors were contributed in establishing the current study as follows:

Research design: R R. H, Z O H, A A. A and M N. J. Collecting of the samples: Z O H and M N. J

Laboratory works, data analysis: A A. A. Writing and editing of the manuscript: R R. H

References

1. Bolocan AS, Upadrasta A, Bettio PHA, Clooney AG, Draper LA, Ross RP, et al. Evaluation of Phage Therapy in the Context of *Enterococcus faecalis* and Its Associated Diseases. *Viruses*. 2019; 11(4): 366. <https://doi.org/10.3390/v11040366>.
2. Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of *Enterococci*. *Microbiol Spectr*. 2019; 7(4): 10. <https://doi.org/10.1128/microbiolspec.GPP3-0053-2018>.
3. Sirichoat A, Flórez AB, Vázquez L, Buppasiri P, Panya M, Lulitanond V, et al. Antibiotic Resistance-Susceptibility Profiles of *Enterococcus faecalis* and *Streptococcus* spp. From the Human Vagina, and Genome Analysis of the Genetic Basis of Intrinsic and Acquired Resistances. *Front Microbiol*. 2020; 11: 1438. <https://doi.org/10.3389/fmicb.2020.01438>.
4. Tagliabue A, Rappuoli R. Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. *Front Immunol*. 2018; 9: 1068. <https://doi.org/10.3389/fimmu.2018.01068>.
5. Mahmood BSh. Silver Nanoparticles and their Role in Gene Expression of Motility Gene motB and Repression of AI-2-Controlled Gene. *Baghdad Sci J*. 2020; 17(3): 916-923. [https://doi.org/10.21123/bsj.2020.17.3\(Suppl.\).0916](https://doi.org/10.21123/bsj.2020.17.3(Suppl.).0916).
6. Abdul Alaameri SK, Al-Hayanni HSA. Antibacterial and anti-biofilm effects of Sumac (*Rhus coriaria* L) fruits extracts against some multidrug-resistant pathogenic bacteria. *J Fac Med Baghdad*. 2022; 64(3): 183-188. <https://doi.org/10.32007/jfacmedbagdad.6431964>.
7. Simmonds P, Aiewsakun P. Virus classification - where do you draw the line? *Arch Virol*. 2018; 163(8): 2037-2046. <https://doi.org/10.1007/s00705-018-3938-z>.
8. García R, Latz S, Romero J, Higuera G, García K, Bastías R. Bacteriophage Production Models: An Overview. *Front Microbiol*. 2019; 10: 1187. <https://doi.org/10.3389/fmicb.2019.01187>.

9. Abedon ST, Danis-Wlodarczyk KM, Wozniak DJ. Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. Pharmaceuticals (Basel). 2021; 14(10): 1019. <https://doi.org/10.3390/ph14101019>.
10. Khalifa L, Gelman D, Shlezinger M, Dessal AL, Copenhagen-Glazer S, Beyth N, et al. Defeating Antibiotic- and Phage-Resistant *Enterococcus faecalis* Using a Phage Cocktail in Vitro and in a Clot Model. Front Microbiol. 2018; 9: 326. <https://doi.org/10.3389/fmicb.2018.00326>.
11. Ahmed ShH, Hafidh RR. The Isolation of specifically lytic phages along with their extracted endolysins as antibacterial agents to MDR *Enterococcus faecalis*. Res J Pharm Technol. 2021; 14(9): 4547-4. <https://doi.org/10.52711/0974-360X.2021.00791>
12. Jassas MN, Hafidh RR. Characterization of the Antibacterial, Antibiofilm Activities, and Genetic Structure of Endolysin Extracted from *Enterococcus faecalis* Phage. Int J Drug Deliv Technol. 2021; 11(3): 817-826. <https://www.myresearchjournals.com/index.php/IJDDT/article/view/6380>.
13. Song M, Wu D, Hu Y, Luo H, Li G. Characterization of an *Enterococcus faecalis* Bacteriophage vB_EfaM_LG1 and Its Synergistic Effect With Antibiotic. Front Cell Infect Microbiol. 2021; 11: 698807. <https://doi.org/10.3389/fcimb.2021.698807>
14. De Almeida CV, Taddei A, Amedei A. The controversial role of *Enterococcus faecalis* in colorectal cancer. Ther Adv Gastroenterol. 2018; 11: 175628481878360. <https://doi.org/10.1177/1756284818783606>.
15. Iseberg HD. Clinical microbiology procedures handbook. Washington DC: ASM Press; 2004. <https://www.clinmicronow.org/doi/book/10.1128/9781683670438.CMPH>
16. Balouri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016; 6(2): 71-79. <https://doi.org/10.1016/j.jpha.2015.11.005>.
17. Alsaadi LAS. Molecular detection of the mex efflux pumps genes in extensively drug-resistant and pandrug-resistant *Pseudomonas aeruginosa* isolated from Iraqi patients in Diyala. World Bull Public Health. 2022; 10: 97-105. <https://scholarexpress.net/index.php/wbph/article/view/981>.
18. Patel JB. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. M100, Wayne PA: Clinical and Laboratory Standards Institute; 2020. <https://clsi.org/standards/products/microbiology/documents/m100/>
19. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001; 48(1): 5-16. https://doi.org/10.1093/jac/48.suppl_1.5.
20. Jurczak-Kurek A, Gąsior T, Nejman-Faleńczyk B, Bloch S, Dydecka A, Topka G, et al. Biodiversity of bacteriophages: morphological and biological properties of a large group of phages isolated from urban sewage. Sci Rep. 2016; 6: 34338. <https://doi.org/10.1038/srep34338>.
21. Ali RM, Abdulmir SA, Kadhim RS. Extraction, purification and therapeutic use of bacteriophage endolysin against multi-drug resistant *Staphylococcus aureus*: In vivo and in vitro study. J Contemp Med Sci. 2018; 4: 33-38. <https://www.jocms.org/index.php/jcms/article/view/336>.
22. Jasim HN, Hafidh RR, Abdulmir AS. Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant *Acinetobacter baumannii*: in vitro and in vivo study. Iran J Basic Med Sci 2018; 21: 1100-1108. <https://doi.org/10.22038/IJBMS.2018.27307.6665>.
23. Mohammed AR. Modifying Plaque assay and Clearance test as tools in determination of phage typing for *E. Coli* bacterial interspecies. Baghdad Sci J. 2013; 10(1): 161-167. <https://doi.org/10.21123/bsj.2013.10.1.161-167>
24. Lin E, Bhusal Y, Horwitz D, Shelburne SA, Trautner BW. Overtreatment of Enterococcal Bacteriuria. Arch Intern Med. 2012; 172(1): 33-38. <https://doi.org/10.1001/archinternmed.2011.565>.
25. Li M, Yang F, Lu Y, Huang W. Identification of *Enterococcus faecalis* in a patient with urinary-tract infection based on metagenomic next-generation sequencing: a case report. BMC Infect Dis. 2020; 20: 467. <https://doi.org/10.1186/s12879-020-05179-0>.
26. Jafarzadeh SR, Tajbakhsh E, Momtaz H, Kabiri SM. Prevalence of Virulence Genes and Antibiotic Resistance Pattern in *Enterococcus faecalis* Isolated from Urinary Tract Infection in Shahrekord, Iran. Rep Biochem Mol Biol. 2021; 10(1): 50-59. <https://doi.org/10.52547/rbmb.10.1.50>.
27. Ghalavand Z, Alebouyeh M, Ghanati K, Azimi L, Rashidan M. Genetic relatedness of the *Enterococcus faecalis* isolates in stool and urine samples of patients with community-acquired urinary tract infection. Gut pathogens. 2020; 12: 42. <https://doi.org/10.1186/s13099-020-00380-7>.
28. Palmer KL, Kos VN, Gilmore MS. Horizontal Gene Transfer and the Genomics of Enterococcal Antibiotic Resistance. Curr Opin Microbiol. 2010; 13: 632-639. <https://doi.org/10.1016/j.mib.2010.08.004>.

29. Chatterjee A, Johnson CN, Luong P, Hullahalli K, McBride SW, Schubert AM, et al. Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of *Enterococci*. *Infect Immun*. 2019; 87 (6): e00085-19. <https://doi.org/10.1128/IAI.00085-19>.
30. Shlezinger M, Copenhagen-Glazer S, Gelman D, Beyth N, Hazan R. Eradication of Vancomycin-Resistant *Enterococci* by Combining Phage and Vancomycin. *Viruses* 2019; 11(10): 954. <https://doi.org/10.3390/v11100954>.
31. Zaidan IA, AL-Kazaz AA, Mohammed AS. Effect the combination of antibiotics on clinical isolates of *Staphylococcus aureus*. *Baghdad Sci J*. 2009; 6 (4): 683-92. <https://doi.org/10.21123/bsj.2009.6.4.683-692>
32. Melconian AK, Al-Baldawi MS, Al-Falahi MA. Effect of Subinhibitory concentration of Antibiotic on Bacterial Adherence to Orthopedic Prosthetic Device. *Baghdad Sci J*. 2007; 4 (1): 28-34. <https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/764>.
33. Zhao Y, Feng L, Zhou B, Zhang X, Yao Z, Wang L, et al. A newly isolated bacteriophage vB8388 and its synergistic effect with aminoglycosides against multi-drug resistant *Klebsiella oxytoca* strain FK-8388. *Microb. Pathog.* 2023; 174: 105906. <https://doi.org/10.1016/j.micpath.2022.105906>
34. Manohar P, Madurantakam Royam M, Loh B, Bozdogan B, Nachimuthu R, Leptih S. Synergistic Effects of Phage-Antibiotic Combinations against *Citrobacter amalonaticus*. *ACS Infect Dis*. 2022 14; 8(1): 59-65. <https://doi.org/10.1021/acsinfecdis.1c00117>.
35. Hong HW, Kim YD, Jang J, Kim MS, Song M, Myung H. Combination Effect of Engineered Endolysin EC340 With Antibiotics. *Front Microbiol*. 2022 Feb 15; 13: 821936. <https://doi.org/10.3389/fmicb.2022.821936>.

تقدير التأثير التآزري خارج الجسم الحي ل اندوليسين العاثيات مع الفانكوميسين على العزلات المحلية العراقية ل *Enterococcus faecalis*

رند رياض حافظ¹، زينب عدي حامد²، عبدالله عباس عوني³، منال ناصر جساس⁴

¹ افرح الأحياء المجهرية، كلية الطب، جامعة بغداد، بغداد، العراق.

² قسم الصيدلة، كلية بغداد للعلوم الطبية، بغداد، العراق.

³ وزارة الصحة، مديرية صحة بغداد-الكرخ، مستشفى الفرات العام، بغداد، العراق.

⁴ شعبة الأحياء المجهرية، قسم المختبر، مستشفى غازي الحريري للجراحة التخصصية، بغداد، العراق.

الخلاصة

من المعروف أن المكورات المعوية البرازية تسبب العديد من الالتهابات الخطيرة مع طفرة في تطور سلالات مقاومة للمضادات الحيوية، وخاصة إلى الفانكوميسين. العاثيات البكتيرية وأنزيمات الإندوليسين الخاصة بها لديها القدرة على التأثير على خلايا بكتيرية معينة وتحليلها مما يجعلها علاجاً بديلاً ممكناً للسلالات المقاومة للمضادات الحيوية. هدفت الدراسة على تقدير التأثير التآزري للعاثية / خليط العاثية / الإندوليسين مع فانكوميسين على المكورات المعوية البرازية المعزولة من عينات البول. تم إجراء كشف كامل لنوع المقاومة للمضادات الحيوية لـ 17 من المكورات المعوية البرازية مع التأكيد على الحساسية للفانكوميسين. تم عزل العاثيات البكتيرية من البيئة المحلية. تم حساب العدوى ومعدل التغطية للعاثية وخليط العاثية. تم عزل إنزيم العاثية البكتيرية بواسطة الكروماتوغرافيا. تم اختبار التأثير التآزري بواسطة اختبار الحد من التعرر لتقييم مستوى الحد من النمو. وجد أن 6/17 من عزلات البراز كانت مقاومة للفانكوميسين، و 7/17 عزلات كانت متوسطة المقاومة، و 4/17 كانت حساسة للفانكوميسين. تم تحديد ثلاث عاثيات بكتيرية بمعدل عدوى 100% و 76.4% و 88.2%. وأسفر كوكتيل العاثيات عن معدل 100% من العدوى و 91.6% من معدل التغطية. كان الانخفاض في مستوى النمو للمكورات البرازية بعد العلاج بخليط العاثية / الفانكوميسين / خليط من الفانكوميسين وخليط العاثية فعالاً. تأثير التآزر من فانكوميسين جنباً إلى جنب مع خليط العاثية خفضت بشكل كبير نمو 70.6% من العزلات. تم الكشف عن النشاط المضاد للبكتيريا من فانكوميسين بالإضافة إلى علاج الإندوليسين بطريقة تعتمد على الوقت. أوضح التأثير التآزري للفانكوميسين مع العاثية / الإندوليسين طريقة فعالة لعلاج عزلات المكورات البرازية المقاومة للمضادات الحيوية للتغلب على هذه المشكلة السريرية الناشئة.

الكلمات المفتاحية: العاثيات البكتيرية، الإندوليسين، البكتيريا متعددة المقاومة للأدوية، العلاج بالعاثيات، المكورات المعوية البرازية.